NTRK1 and acute myeloid leukemia: The approvals of midostaurin, gilteritinib, and quizartinib have reshaped the prognosis of FLT3-mutant AML, demonstrating that precision targeting of a single receptor tyrosine kinase can alter the natural history of a once uniformly high-risk disease.